HLB BioStep Co

HLB BioStep Co Tangible Book Value per Share

The Tangible Book Value per Share of HLB BioStep Co (278650.KQ) as of Nov 1, 2026 is 1,104.51 KRW. In the previous year, Tangible Book Value per Share was 1,188.10 KRW — a change of -7.04% (lower).

Tangible Book Value per Share

1,104.51KRW

YoY

-7.04%

Last updated:

Tangible Book Value per Share of HLB BioStep Co is 2025 1,104.51 KRW. Tangible Book Value per Share of HLB BioStep Co was 2024 1,188.10 KRW. It decreases by -7.04% lower compared to the previous year.

The HLB BioStep Co Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2018
226.38 KRW
Jan 1, 2019
472.64 KRW
Jan 1, 2020
603.35 KRW
Jan 1, 2021
730.03 KRW
Jan 1, 2022
785.47 KRW
Jan 1, 2023
1,163.51 KRW
Jan 1, 2024
1,188.10 KRW
Jan 1, 2025
1,104.51 KRW
The HLB BioStep Co Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
1,104.51KRW-7.04%
1,188.10KRW+2.11%
1,163.51KRW+48.13%
785.47KRW+7.59%
730.03KRW+21.00%
603.35KRW+27.66%
472.64KRW+108.78%
226.38KRW+31.28%
172.44KRW+113.37%
80.82KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

HLB BioStep Co Stock analysis

What does HLB BioStep Co do? HLB bioStep Co., Ltd. generates revenue through three business segments. The Non-clinical Test Consignment Agency Business segment provides testing for new drugs and evaluates efficacy, pharmacodynamics, and safety of substances. The Bioinfra Business segment designs, constructs, and maintains animal laboratories while delivering equipment. The Pet Medical Business segment develops veterinary medicine and sells companion animal products. Clients include pharmaceutical companies requiring non-clinical testing, research institutions needing laboratory infrastructure, and pet care providers purchasing animal health products. The company's Non-clinical Test Consignment Agency Business serves pharmaceutical firms seeking pre-market substance evaluation. Bioinfra Business targets institutions requiring specialized animal lab facilities and equipment. Pet Medical Business supplies veterinary medicine to pet health markets. Revenue streams are derived from testing fees, laboratory services, equipment sales, and product distribution. HLB bioStep's segments align with pharmaceutical development cycles, animal research infrastructure needs, and companion animal healthcare demands. Testing services are contracted by drug developers, lab construction by research organizations, and veterinary products sold to pet care retailers. The company monetizes expertise in non-clinical testing, lab management, and veterinary product distribution without direct consumer sales. HLB BioStep Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HLB BioStep Co stock

Tangible Book Value per Share of HLB BioStep Co is 1,104.51 KRW in 2025.

Tangible Book Value per Share of HLB BioStep Co changed from 1,188.10 KRW to 1,104.51 KRW, representing a -7.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share HLB BioStep Co since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — HLB BioStep Co

All Key Metrics — HLB BioStep Co